Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
Hematology
Ropeg Interferon is now a preferred therapy for Polycythemia Vera (PV) as per a recent update to the NCCN guidelines. Under which circumstances would you prefer it over Hydroxyurea?
Related Questions
Do you prefer to use 7+3 or CPX-351 as standard induction therapy in younger patients with AML-MRC or t-AML?
Would you re-challenge a CLL patient, who had good response to Zanubrutinib but contracted cryptococcal pneumonia, with another BTK inhibitor?
How should one approach an incidentally found T-cell gene arrangement?
Do complex cytogenetics have any therapeutic or prognostic relevance in CLL?
For AML patients, when do you stop antiinfective agents?
How would you treat an LGL leukemia patient who has been refractory to treatments with cyclosporine, MTX, and cyclophosphamide?
Do you prefer quizartinib over midostaurin with chemotherapy induction for FLT3-ITD mutated AML given the results of QUANTUM-FIRST and preclinical advantages over other FLT3 inhibitors?
How has your approach to utilizing MRD-guided therapy in previously untreated CLL changed since the FLAIR trial, particularly in choosing between continuous versus time-limited treatment?
What is the consensus on giving Pemivibart for Pre-Exposure COVID prophylaxis in immunocompromised patients?
What are your top takeaways in Hematologic Malignancies from ASCO 2023?
